SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Infoblox, Inc. of Class Action Lawsuit and Upcoming Deadline -- BLOX

NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Pomerantz LLP has filed a class action lawsuit against Infoblox, Inc ("Infoblox" or the "Company") (NYSE: BLOX ) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 5:14-cv-02644, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Infoblox between September 6, 2013 and February 10, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Infoblox securities during the Class Period, you have until July 29, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Infoblox develops, markets, and sells automated network control solutions worldwide. Its appliance-based solution combines real-time IP address management with the automation of network control, and network change and configuration management processes in physical and virtual appliances.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, Defendants made numerous statements regarding Infoblox's financial strength that were false and misleading in light of Defendants' concealment of the fats that: (i) the Company's Federal business prospects were weak and would continue to be weak for the foreseeable future; (ii) the Company had been implementing enormous discounting in order to maintain market share; and (iii) the Company was failing to close on big-ticket deals that had previously driven its revenue growth.

Infoblox insiders – including the Individual Defendants – sold significant amounts of Company stock at artificially inflated prices, reaping considerable profits at a time when these individuals were privy to material adverse information concerning the Company's financial prospects. The Individual Defendants and other directors and senior executives sold their shares after publicly providing guidance that they knew or should have known was baseless and unreasonable. Infoblox management further delayed correcting their previously-issued guidance in order to continue to sell shares at inflated prices.

On February 10, 2014, after the market close, Infoblox provided preliminary fiscal second quarter ("2Q") 2014 results and updated its outlook for fiscal year 2014. For the first time, the Company disclosed that it had been "discounting enormously to get deals." The Company revised its guidance downward both for its second quarter ending January 31, 20014 and for its fiscal year ending July 31, 2014.  The Company announced that it now predicted revenue of $60 to $61 million for 2Q 2014, down from the previous expectation of $65 to $66 million and a non-GAAP earnings per share ("EPS") of $0.10 to $0.12, versus previous estimates of $0.09 to $0.11. For its full year outlook, Infoblox revised external revenue projections to $250 to $254 million, down from previous guidance over the last two quarters of $270 to $276 million. EPS was updated to be $0.30 to $0.34 diluted earnings per share, lower than previous guidance over the last two quarters for full year earnings of $0.44 to $0.54.

On this news, shares of Infoblox declined $15.95 per share, or over 48.12%, to close at $17.19 per share on February 11, 2014.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

Robert S. Willoughby Pomerantz LLP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 250

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 254

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 353

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 155

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 143

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 313

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Explore Rob Zombie's Unique Art Exhibition in Kent Connetcticut

Updated Category News Views 226

Rob Zombie's Art Exhibition: "What Lurks on Channel X?" Morrison Gallery is excited to announce the first-ever exhibition of Rob Zombie's provocative artwork titled "What Lurks on Channel X?" This unique showcase celebrates the artistry of the renowned rock musician and filmmaker. The exhibition is set to open for public viewing, bringing an array of Zombie's dynamic...

Continue Reading
Unlocking Over $11M Annually: Modernizing Industrial Systems

Updated Category News Views 237

Revolutionizing Industrial Automation for Greater Savings Modernization is key for industrial companies seeking to thrive, especially in today’s competitive landscape. A recent enlightening study has unveiled a significant opportunity: organizations can potentially reclaim $11.28 million annually by shifting away from outdated closed automation systems. This information...

Continue Reading
Investors on Alert: Security Class Action for StubHub Holdings

Updated Category News Views 159

Investors on Alert: Security Class Action for StubHub Holdings National shareholder rights firm Hagens Berman is reaching out to investors of StubHub Holdings, Inc. (NYSE: STUB) following news of a significant deadline in a prospective securities class action. This legal inquiry focuses on whether the Initial Public Offering (IPO) documents from StubHub, made available to...

Continue Reading
Melexis Enhances Shareholder Value with Strategic Buyback

Updated Category News Views 240

Melexis Enhances Shareholder Value with Strategic Buyback Melexis continues to demonstrate its commitment to enhancing shareholder value with an active share buy-back program. Following the announcement made late last year regarding the initiation of this program, the company recently announced the purchase of 47,500 shares on Euronext Brussels during a specified period...

Continue Reading
John Manimas Unveils Breakthrough in Ancient Geometry Puzzle

Updated Category News Views 249

The Remarkable Discovery of John Manimas John Manimas, renowned for his engaging exploration of mathematical mysteries, has recently announced a significant advancement in the realm of geometry. He claims to have discovered a positive solution to the age-old Pythagorean riddle: the question of whether one can construct a circle that is exactly equal in area to a given...

Continue Reading